Press Releases



March 30, 2022

Olympic Ophthalmics Announces FDA Clearance and Availability of Its Next-Generation iTear®100 Neurostimulation Device, Expanded Patent Portfolio, and Further Clinical Studies

Read Article


November 3, 2021

DIY Commercialization, with Olympic Ophthalmics’ Michael Gertner, MD.

Read Article


Jun 06, 2021

Arctic Vision Announces Exclusive Licensing Agreement with Olympic Ophthalmics for iTear®100 for the Treatment of Dry Eye Disease in Greater China, South Korea and ASEAN Countries.

Read Article



April 22, 2021

Olympic Ophthalmics Announces Issuance of Two Seminal Patents for its Neuromodulation Technology.

Read Article



Nov 17, 2020

Clinical Results: Safety and Efficacy of iTear®100.

Read Article



September 15, 2020

Dry Eye: The Nose Knows.

Learn how neurostimulation is becoming a viable treatment option for patients who have exhausted their options.

Read Article



May 22, 2020

Olympic Ophthalmics Presents Clinical Evidence for iTear®100

Read Article



May 14, 2020

Olympic Ophthalmics Receives FDA Clearance for iTear®100 Neurostimulator.

Read Article



June 15, 2019

Dry Eye Therapy: Getting Nosy

Understand the science behind nasal stimulation.

Read Article



FDA Approval of iTear®100: An electromechanical nerve stimulator that is used externally on the nose and increases tear production.

Read Article



Ready to try iTEAR®100?


Get iTEAR®100

More questions?

iTEAR® Clinical Trial